Premium
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR‐ABL inhibitors in lymphomas
Author(s) -
Rinaldi Andrea,
Ponzoni Maurilio,
Uccella Silvia,
Rossi Davide,
Gaidano Gianluca,
Facchetti Fabio,
Pruneri Giancarlo,
Tibiletti Maria Grazia,
Capella Carlo,
Zucca Emanuele,
Doglioni Claudio,
Catapano Carlo,
Bertoni Francesco
Publication year - 2011
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.981
Subject(s) - syk , cancer research , tyrosine kinase , in vitro , medicine , kinase , chemistry , receptor , biochemistry
The B cell receptor (BCR) signalling pathway is believed to play a major role in B cell lymphoma growth and survival [1,2]. SYK is a critical non-receptor tyrosine kinase involved in the BCR signalling, that, when activated, leads to intracellular calcium mobilization, activation of AKT, mitogen-activated protein kinases and NFkB. A relatively strong expression of SYK can be demonstrated in the vast majority of non-Hodgkin lymphoma subtypes [3], and inhibition of SYK has been